Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as relacorilant, Relacorilant
Relacorilant with nab-paclitaxel · 1 trial · 1 indication
The Maximum Tolerated Dose and the development regimen of relacorilant with nab-paclitaxel was determined by the number of participants with dose-limiting toxicities as defined in the protocol.
| Arm | Type | Description |
|---|---|---|
| Relacorilant with nab-paclitaxel | EXPERIMENTAL | Participants will be treated with relacorilant in combination with nab-paclitaxel at escalating dose levels in either a Continuous-Dosing Regimen or an Intermittent-Dosing Regimen. |
| Name | Type | Description |
|---|---|---|
| Relacorilant with nab-paclitaxel | DRUG | Relacorilant is supplied as capsules for oral dosing. Nab-paclitaxel administered as an IV infusion. |
Inclusion Criteria: * Participants with advanced or metastatic solid tumors who have disease progression after treatment with available therapies and for whom nab-paclitaxel treatment is appropriate. * Measurable or evaluable disease. * Up to 3 prior cytotoxic chemotherapeutics regimens or myelosup...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
Relacorilant is an investigational small molecule being studied for use in Cushing syndrome, solid tumors, recurrent ovarian cancer, adenocarcinoma, and hepatic impairment. It is being developed by Corcept Therapeutics Incorporated (CORT) and is currently in Phase 2 clinical development for these indications.
Relacorilant is a selective glucocorticoid receptor modulator. It works by binding to the glucocorticoid receptor, which is involved in regulating various physiological processes. This mechanism is being studied for its potential effects in oncology and endocrine conditions like Cushing syndrome.
Relacorilant is being developed by Corcept Therapeutics Incorporated, a biopharmaceutical company traded on NASDAQ under the ticker symbol CORT. The company is conducting clinical trials to evaluate the drug's safety and efficacy across multiple indications.
Relacorilant is in Phase 2 clinical development. It has completed Phase 1 and Phase 2 trials, with one active Phase 2 study currently recruiting participants. The drug is investigational and has not been approved by regulatory authorities for any indication.
Relacorilant has been studied in several clinical trials. NCT02762981 evaluated it with nab-paclitaxel in solid tumors, NCT03604198 is an extension study in Cushing syndrome, NCT05347979 assessed its effect on drug interactions, and NCT07259317 is an ongoing Phase 2 trial in metastatic pancreatic adenocarcinoma.
Yes, Relacorilant is also known as CORT125134. The clinical trial NCT02762981, which studied the drug in combination with nab-paclitaxel in solid tumors, explicitly refers to Relacorilant as CORT125134 in its title.